Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Activities of Daily Living and Their Relationship to Health-Related Quality of Life in Patients with Parkinson Disease After Subthalamic Nucleus Deep Brain Stimulation.

Gorecka-Mazur A, Furgala A, Krygowska-Wajs A, Pietraszko W, Kwinta B, Gil K.

World Neurosurg. 2019 May;125:e552-e562. doi: 10.1016/j.wneu.2019.01.132. Epub 2019 Feb 1.

PMID:
30716489
2.

Acute treatment with doxorubicin induced neurochemical impairment of the function of dopamine system in rat brain structures.

Antkiewicz-Michaluk L, Krzemieniecki K, Romanska I, Michaluk J, Krygowska-Wajs A.

Pharmacol Rep. 2016 Jun;68(3):627-30. doi: 10.1016/j.pharep.2016.01.009. Epub 2016 Feb 13.

PMID:
26991377
3.

The effect of subthalamic deep brain stimulation on gastric motility in Parkinson's disease.

Krygowska-Wajs A, Furgala A, Gorecka-Mazur A, Pietraszko W, Thor P, Potasz-Kulikowska K, Moskala M.

Parkinsonism Relat Disord. 2016 May;26:35-40. doi: 10.1016/j.parkreldis.2016.02.010. Epub 2016 Feb 15.

PMID:
26952698
4.

[Evaluation of heart rate and blood pressure variability in Parkinson's disease patients after bilateral subthalamic deep brain stimulation].

Furgała A, Górecka-Mazur A, Fiszer U, Pietraszko W, Thor P, Moskała M, Potasz K, Bukowczan M, Polak J, Krygowska-Wajs A.

Przegl Lek. 2015;72(5):246-52. Polish.

PMID:
26817327
5.

Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders.

Ogaki K, Koga S, Heckman MG, Fiesel FC, Ando M, Labbé C, Lorenzo-Betancor O, Moussaud-Lamodière EL, Soto-Ortolaza AI, Walton RL, Strongosky AJ, Uitti RJ, McCarthy A, Lynch T, Siuda J, Opala G, Rudzinska M, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Puschmann A, Nishioka K, Funayama M, Hattori N, Parisi JE, Petersen RC, Graff-Radford NR, Boeve BF, Springer W, Wszolek ZK, Dickson DW, Ross OA.

Neurology. 2015 Dec 8;85(23):2016-25. doi: 10.1212/WNL.0000000000002170. Epub 2015 Nov 11.

6.

Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson's disease (PANDA): a double-blind, randomised, placebo-controlled trial.

Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M; PANDA study group.

Lancet Neurol. 2015 Dec;14(12):1161-70. doi: 10.1016/S1474-4422(15)00243-4. Epub 2015 Oct 19.

PMID:
26494524
7.

Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies.

Labbé C, Ogaki K, Lorenzo-Betancor O, Soto-Ortolaza AI, Walton RL, Rayaprolu S, Fujioka S, Murray ME, Heckman MG, Puschmann A, McCarthy A, Lynch T, Siuda J, Opala G, Rudzinska M, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Sanotsky Y, Rektorová I, McLean PJ, Rademakers R, Ertekin-Taner N, Hassan A, Ahlskog JE, Boeve BF, Petersen RC, Maraganore DM, Adler CH, Ferman TJ, Parisi JE, Graff-Radford NR, Uitti RJ, Wszolek ZK, Dickson DW, Ross OA.

Neurology. 2015 Nov 10;85(19):1680-6. doi: 10.1212/WNL.0000000000001946. Epub 2015 Sep 2. Erratum in: Neurology. 2015 Nov 10;85(19):1728.

8.

DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients.

Lorenzo-Betancor O, Ogaki K, Soto-Ortolaza AI, Labbe C, Walton RL, Strongosky AJ, van Gerpen JA, Uitti RJ, McLean PJ, Springer W, Siuda J, Opala G, Krygowska-Wajs A, Barcikowska M, Czyzewski K, McCarthy A, Lynch T, Puschmann A, Rektorova I, Sanotsky Y, Vilariño-Güell C, Farrer MJ, Ferman TJ, Boeve BF, Petersen RC, Parisi JE, Graff-Radford NR, Dickson DW, Wszolek ZK, Ross OA.

Eur J Neurol. 2015 Sep;22(9):1323-5. doi: 10.1111/ene.12770.

9.

Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson's Disease Locus.

Labbé C, Ogaki K, Lorenzo-Betancor O, Carrasquillo MM, Heckman MG, McCarthy A, Soto-Ortolaza AI, Walton RL, Lynch T, Siuda J, Opala G, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Dickson DW, Uitti RJ, Wszolek ZK, Ross OA.

PLoS One. 2015 Jun 19;10(6):e0128586. doi: 10.1371/journal.pone.0128586. eCollection 2015.

10.

Peripheral vagus nerve stimulation significantly affects lipid composition and protein secondary structure within dopamine-related brain regions in rats.

Surowka AD, Krygowska-Wajs A, Ziomber A, Thor P, Chrobak AA, Szczerbowska-Boruchowska M.

Neuromolecular Med. 2015 Jun;17(2):178-91. doi: 10.1007/s12017-015-8349-7. Epub 2015 Apr 19.

11.

Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson's disease.

Shannon B, Soto-Ortolaza A, Rayaprolu S, Cannon HD, Labbé C, Benitez BA, Choi J, Lynch T, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, Barcikowska M, Van Gerpen JA, Uitti RJ, Springer W, Cruchaga C, Wszolek ZK, Ross OA.

Neurobiol Aging. 2014 Aug;35(8):1958.e1-2. doi: 10.1016/j.neurobiolaging.2014.03.004. Epub 2014 Mar 5.

12.

GWAS risk factors in Parkinson's disease: LRRK2 coding variation and genetic interaction with PARK16.

Soto-Ortolaza AI, Heckman MG, Labbé C, Serie DJ, Puschmann A, Rayaprolu S, Strongosky A, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Lynch T, Uitti RJ, Wszolek ZK, Ross OA.

Am J Neurodegener Dis. 2013 Nov 29;2(4):287-99. eCollection 2013.

13.

Novel A18T and pA29S substitutions in α-synuclein may be associated with sporadic Parkinson's disease.

Hoffman-Zacharska D, Koziorowski D, Ross OA, Milewski M, Poznanski JA, Jurek M, Wszolek ZK, Soto-Ortolaza A, Awek JAS, Janik P, Jamrozik Z, Potulska-Chromik A, Jasinska-Myga B, Opala G, Krygowska-Wajs A, Czyzewski K, Dickson DW, Bal J, Friedman A.

Parkinsonism Relat Disord. 2013 Nov;19(11):1057-1060. doi: 10.1016/j.parkreldis.2013.07.011. Epub 2013 Aug 2.

14.

TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease.

Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Josephs KA, Knopman DS, White CL 3rd, Caselli R, Mackenzie IR, Miller BL, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, Barcikowska M, Younkin SG, Petersen RC, Ertekin-Taner N, Uitti RJ, Meschia JF, Boylan KB, Boeve BF, Graff-Radford NR, Wszolek ZK, Dickson DW, Rademakers R, Ross OA.

Mol Neurodegener. 2013 Jun 21;8:19. doi: 10.1186/1750-1326-8-19.

15.

Chronic impairment of the vagus nerve function leads to inhibition of dopamine but not serotonin neurons in rat brain structures.

Ziomber A, Thor P, Krygowska-Wajs A, Załęcki T, Moskała M, Romańska I, Michaluk J, Antkiewicz-Michaluk L.

Pharmacol Rep. 2012;64(6):1359-67.

16.

Efficacy of deep brain stimulation of the subthalamic nucleus on autonomic dysfunction in patients with Parkinson's disease.

Pietraszko W, Furgala A, Gorecka-Mazur A, Thor P, Moskala M, Polak J, Surowka AD, Krygowska-Wajs A.

Folia Med Cracov. 2013;53(2):15-22.

17.

Visual feedback training using WII Fit improves balance in Parkinson's disease.

Zalecki T, Gorecka-Mazur A, Pietraszko W, Surowka AD, Novak P, Moskala M, Krygowska-Wajs A.

Folia Med Cracov. 2013;53(1):65-78.

18.

A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants.

Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Bertram L, Bozi M, Barcikowska M, Crosiers D, Clarke CE, Facheris MF, Farrer M, Garraux G, Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon BS, Jamrozik Z, Krygowska-Wajs A, Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Libioulle C, Murata M, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Meitnger T, Zimprich A, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Strom TM, Theuns J, Tan EK, Toda T, Tomiyama H, Uitti RJ, Van Broeckhoven C, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yomono HS, Yueh KC, Zhao Y, Gasser T, Maraganore D, Krüger R; GEOPD consortium.

J Med Genet. 2012 Nov;49(11):721-6. doi: 10.1136/jmedgenet-2012-101155. Erratum in: J Med Genet. 2013 Mar;50(3):202.

19.

Elemental micro-imaging and quantification of human substantia nigra using synchrotron radiation based x-ray fluorescence--in relation to Parkinson's disease.

Szczerbowska-Boruchowska M, Krygowska-Wajs A, Adamek D.

J Phys Condens Matter. 2012 Jun 20;24(24):244104. doi: 10.1088/0953-8984/24/24/244104. Epub 2012 May 18.

PMID:
22595486
20.

The influence of electrical stimulation of vagus nerve on elemental composition of dopamine related brain structures in rats.

Szczerbowska-Boruchowska M, Krygowska-Wajs A, Ziomber A, Thor P, Wrobel P, Bukowczan M, Zizak I.

Neurochem Int. 2012 Jul;61(2):156-65. doi: 10.1016/j.neuint.2012.04.018. Epub 2012 Apr 25.

PMID:
22561408
21.

Translation initiator EIF4G1 mutations in familial Parkinson disease.

Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, Le Rhun E, Mutez E, Larvor L, Duflot A, Vanbesien-Mailliot C, Kreisler A, Ross OA, Nishioka K, Soto-Ortolaza AI, Cobb SA, Melrose HL, Behrouz B, Keeling BH, Bacon JA, Hentati E, Williams L, Yanagiya A, Sonenberg N, Lockhart PJ, Zubair AC, Uitti RJ, Aasly JO, Krygowska-Wajs A, Opala G, Wszolek ZK, Frigerio R, Maraganore DM, Gosal D, Lynch T, Hutchinson M, Bentivoglio AR, Valente EM, Nichols WC, Pankratz N, Foroud T, Gibson RA, Hentati F, Dickson DW, Destée A, Farrer MJ.

Am J Hum Genet. 2011 Sep 9;89(3):398-406. doi: 10.1016/j.ajhg.2011.08.009.

22.

VPS35 mutations in Parkinson disease.

Vilariño-Güell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Soto-Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, Conibear E, Wasserman WW, Aasly JO, Burkhard PR, Djaldetti R, Ghika J, Hentati F, Krygowska-Wajs A, Lynch T, Melamed E, Rajput A, Rajput AH, Solida A, Wu RM, Uitti RJ, Wszolek ZK, Vingerhoets F, Farrer MJ.

Am J Hum Genet. 2011 Jul 15;89(1):162-7. doi: 10.1016/j.ajhg.2011.06.001. Erratum in: Am J Hum Genet. 2011 Aug 12;89(2):347.

23.

Death-associated protein kinase 1 variation and Parkinson's disease.

Dachsel JC, Wider C, Vilariño-Güell C, Aasly JO, Rajput A, Rajput AH, Lynch T, Craig D, Krygowska-Wajs A, Jasinska-Myga B, Opala G, Barcikowska M, Czyzewski K, Wu RM, Heckman MG, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA.

Eur J Neurol. 2011 Aug;18(8):1090-3. doi: 10.1111/j.1468-1331.2010.03255.x. Epub 2010 Nov 30.

PMID:
21749573
24.

Ecchordosis physaliphora - a case report and a review of notochord-derived lesions.

Adamek D, Malec M, Grabska N, Krygowska-Wajs A, Gałązka K.

Neurol Neurochir Pol. 2011 Mar-Apr;45(2):169-73. Review.

PMID:
21574122
25.

Human leukocyte antigen variation and Parkinson's disease.

Puschmann A, Verbeeck C, Heckman MG, Soto-Ortolaza AI, Lynch T, Jasinska-Myga B, Opala G, Krygowska-Wajs A, Barcikowska M, Uitti RJ, Wszolek ZK, Ross OA.

Parkinsonism Relat Disord. 2011 Jun;17(5):376-8. doi: 10.1016/j.parkreldis.2011.03.008. Epub 2011 Apr 11.

26.

An independent replication of PARK16 in Asian samples.

Vilariño-Güell C, Ross OA, Aasly JO, White LR, Rajput A, Rajput AH, Lynch T, Krygowska-Wajs A, Jasinska-Myga B, Opala G, Barcikowska M, Lee MC, Hentati F, Uitti RJ, Wszolek ZK, Farrer MJ, Wu RM.

Neurology. 2010 Dec 14;75(24):2248-9. doi: 10.1212/WNL.0b013e318202031f. No abstract available.

27.

Association of pyridoxal kinase and Parkinson disease.

Vilariño-Güell C, Wider C, Aasly JO, White LR, Rajput A, Rajput AH, Lynch T, Krygowska-Wajs A, Jasinska-Myga B, Opala G, Barcikowska M, Czyzewski K, Wu RM, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA.

Ann Neurol. 2010 Mar;67(3):409-11. doi: 10.1002/ana.21962. No abstract available.

PMID:
20373354
28.

[Effects of deep brain stimulation on dysfunctions of the autonomic nervous system in Parkinson's disease].

Libionka W, Krygowska-Wajs A, Stachura K, Pietraszko W, Moskała M.

Przegl Lek. 2010;67(9):741-4. Review. Polish.

PMID:
21387817
29.

Calbindin-1 association and Parkinson's disease.

Soto-Ortolaza AI, Behrouz B, Wider C, Vilariño-Güell C, Heckman MG, Aasly JO, Mark Gibson J, Lynch T, Jasinska-Myga B, Krygowska-Wajs A, Opala G, Barcikowska M, Czyzewski K, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA.

Eur J Neurol. 2010 Feb;17(2):208-11. doi: 10.1111/j.1468-1331.2009.02769.x. Epub 2009 Aug 5.

PMID:
19674066
30.

Characterization of DCTN1 genetic variability in neurodegeneration.

Vilariño-Güell C, Wider C, Soto-Ortolaza AI, Cobb SA, Kachergus JM, Keeling BH, Dachsel JC, Hulihan MM, Dickson DW, Wszolek ZK, Uitti RJ, Graff-Radford NR, Boeve BF, Josephs KA, Miller B, Boylan KB, Gwinn K, Adler CH, Aasly JO, Hentati F, Destée A, Krygowska-Wajs A, Chartier-Harlin MC, Ross OA, Rademakers R, Farrer MJ.

Neurology. 2009 Jun 9;72(23):2024-8. doi: 10.1212/WNL.0b013e3181a92c4c.

31.

GRN 3'UTR+78 C>T is not associated with risk for Parkinson's disease.

Jasinska-Myga B, Wider C, Opala G, Krygowska-Wajs A, Barcikowska M, Czyzewski K, Baker M, Rademakers R, Uitti RJ, Farrer MJ, Ross OA, Wszolek ZK.

Eur J Neurol. 2009 Aug;16(8):909-11. doi: 10.1111/j.1468-1331.2009.02621.x. Epub 2009 Mar 31.

PMID:
19473366
32.

Evaluation of gastric emptying in familial and sporadic Parkinson disease.

Krygowska-Wajs A, Cheshire WP Jr, Wszolek ZK, Hubalewska-Dydejczyk A, Jasinska-Myga B, Farrer MJ, Moskala M, Sowa-Staszczak A.

Parkinsonism Relat Disord. 2009 Nov;15(9):692-6. doi: 10.1016/j.parkreldis.2009.04.003. Epub 2009 May 17.

33.

Increased synphilin-1 expression in human elderly brains with substantia nigra Marinesco bodies.

Krygowska-Wajs A, Lenda T, Adamek D, Moskała M, Kuter K, Kunz J, Smiałowska M, Ossowska K.

Pharmacol Rep. 2008 Nov-Dec;60(6):914-24.

34.

Genetic variation of Omi/HtrA2 and Parkinson's disease.

Ross OA, Soto AI, Vilariño-Güell C, Heckman MG, Diehl NN, Hulihan MM, Aasly JO, Sando S, Gibson JM, Lynch T, Krygowska-Wajs A, Opala G, Barcikowska M, Czyzewski K, Uitti RJ, Wszolek ZK, Farrer MJ.

Parkinsonism Relat Disord. 2008 Nov;14(7):539-43. doi: 10.1016/j.parkreldis.2008.08.003. Epub 2008 Sep 14.

35.

Study of Cu chemical state inside single neurons from Parkinson's disease and control substantia nigra using the micro-XANES technique.

Chwiej J, Adamek D, Szczerbowska-Boruchowska M, Krygowska-Wajs A, Bohic S, Lankosz M.

J Trace Elem Med Biol. 2008;22(3):183-8. doi: 10.1016/j.jtemb.2008.03.006. Epub 2008 Jun 26.

PMID:
18755393
36.

Dopamine beta-hydroxylase -1021C>T association and Parkinson's disease.

Ross OA, Heckman MG, Soto AI, Diehl NN, Haugarvoll K, Vilariño-Güell C, Aasly JO, Sando S, Gibson JM, Lynch T, Krygowska-Wajs A, Opala G, Barcikowska M, Czyzewski K, Uitti RJ, Wszolek ZK, Farrer MJ.

Parkinsonism Relat Disord. 2008 Nov;14(7):544-7. doi: 10.1016/j.parkreldis.2008.07.002. Epub 2008 Aug 22.

37.

Biomolecular investigation of human substantia nigra in Parkinson's disease by synchrotron radiation Fourier transform infrared microspectroscopy.

Szczerbowska-Boruchowska M, Dumas P, Kastyak MZ, Chwiej J, Lankosz M, Adamek D, Krygowska-Wajs A.

Arch Biochem Biophys. 2007 Mar 15;459(2):241-8. Epub 2007 Jan 16.

PMID:
17274943
38.

Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease.

Stocchi F, Fabbri L, Vecsei L, Krygowska-Wajs A, Monici Preti PA, Ruggieri SA.

Clin Neuropharmacol. 2007 Jan-Feb;30(1):18-24.

PMID:
17272966
39.

Investigations of differences in iron oxidation state inside single neurons from substantia nigra of Parkinson's disease and control patients using the micro-XANES technique.

Chwiej J, Adamek D, Szczerbowska-Boruchowska M, Krygowska-Wajs A, Wojcik S, Falkenberg G, Manka A, Lankosz M.

J Biol Inorg Chem. 2007 Feb;12(2):204-11. Epub 2006 Nov 21.

PMID:
17120075
40.

Peripheral mechanisms of intestinal dysmotility in rats with salsolinol induced experimental Parkinson's disease.

Banach T, Zurowski D, Gil K, Krygowska-Wajs A, Marszałek A, Thor PJ.

J Physiol Pharmacol. 2006 Jun;57(2):291-300.

41.

Falls in Parkinson's disease. Causes and impact on patients' quality of life.

Michałowska M, Fiszer U, Krygowska-Wajs A, Owczarek K.

Funct Neurol. 2005 Oct-Dec;20(4):163-8.

PMID:
16483454
42.

Influence of paraquat on dopaminergic transporter in the rat brain.

Ossowska K, Wardas J, Kuter K, Nowak P, Dabrowska J, Bortel A, Labus Ł, Kwieciński A, Krygowska-Wajs A, Wolfarth S.

Pharmacol Rep. 2005 May-Jun;57(3):330-5.

43.

Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism.

Krygowska-Wajs A, Kachergus JM, Hulihan MM, Farrer MJ, Searcy JA, Booij J, Berendse HW, Wolters ECh, Wszolek ZK.

J Neural Transm (Vienna). 2005 Nov;112(11):1487-502. Epub 2005 Mar 23.

PMID:
15785861
44.

Parkinsonism, FXTAS, and FMR1 premutations.

Toft M, Aasly J, Bisceglio G, Adler CH, Uitti RJ, Krygowska-Wajs A, Lynch T, Wszolek ZK, Farrer MJ.

Mov Disord. 2005 Feb;20(2):230-3.

PMID:
15390127
45.

[Advances in the genetic studies in Parkinson's disease].

Krygowska-Wajs A, Wszolek Z.

Neurol Neurochir Pol. 2004 Mar-Apr;38(2):127-36. Review. Polish.

PMID:
15307606
46.

The antibodies against Bordetella pertussis in sera of patients with Parkinson's disease and other non-neurological diseases.

Fiszer U, Tomik B, Grzesiowski P, Krygowska-Wajs A, Walory J, Michałowska M, Palasik W.

Acta Neurol Scand. 2004 Aug;110(2):113-7.

PMID:
15242419
47.

[Current therapies for parkinson's disease. Part II: surgical treatment].

Słowiński J, Wharen RE, Uitti RJ, Wszolek ZK, Krygowska-Wajs A, Mrówka R.

Neurol Neurochir Pol. 2003 May-Jun;37(3):677-86. Review. Polish.

PMID:
14593761
48.

[The current therapies for parkinson's disease. Part I: pharmacological treatment].

Krygowska-Wajs A, Wszolek ZK, Uitti RJ, Słowinski J, Szczudlik A.

Neurol Neurochir Pol. 2003 May-Jun;37(3):665-76. Review. Polish.

PMID:
14593760
49.

[Fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17): clinical criteria].

Wszolek ZK, Krygowska-Wajs A, Barcikowska M.

Neurol Neurochir Pol. 2003 Jan-Feb;37(1):173-84. Polish.

PMID:
12910839
50.

[Early diagnosis of orthostatic hypotension in idopathic Parkinson's disease].

Krygowska-Wajs A, Furgała A, Laskiewicz J, Szczudlik A, Thor PJ.

Folia Med Cracov. 2002;43(1-2):59-67. Polish.

PMID:
12815799

Supplemental Content

Loading ...
Support Center